Chardan医疗保健收购 PHGE 深 沪
等待开盘 02-07 09:30:00 美东时间
3.98
-0.660
-14.22%
华盛通- 最 高8.50
- 今 开4.66
- 成交量 6.02万股
- 最 低 1.81
- 昨 收 4.64
- 总市值 11.85万
- 52周最高 8.50
- 市盈率 静 --
- 换手率 202.10%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2.98万
- 历史最高 8.50
- 量 比 0.48
- 振 幅 144.18%
- 历史最低 0.00
- 每 手 1
- 风险率 1.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for January 27th
JBLU: -7% | JetBlue Airways shares are trading lower after the company reported worse-than-expected Q4 EPS. PHGE: 165% | BiomX shares are trading higher after a 13D filing disclosed that Pyu Pyu Capital
01-27 20:19
BiomX Commences ~$3M Private Placement Of Series Y Convertible Preferred Stock
BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered
2025-12-29 21:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-12-09 01:46
US Stocks Mixed; Dow Falls Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling around ...
2025-12-08 23:04
Earnings Preview For BiomX
BiomX (AMEX:PHGE) is set to give its latest quarterly earnings report on Wednes...
2025-11-12 01:12
BiomX To Provide Latest Update On Phase 1b/2a Clinical Trial Data For BX004 At The North American Cystic Fibrosis Conference
BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data
2024-09-18 20:19
BiomX To Present Phase 1b/2a Clinical Trial Data For BX004 At The ERS Congress 2024
BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients w...
2024-09-03 20:23
BiomX to Effect 1-for-10 Reverse Stock Split
10:19 AM EDT, 08/15/2024 (MT Newswires) -- BiomX (PHGE) said Thursday it plans to effect a 1-for-10 reverse split of its common shares. The shares will start trading on a split-adjusted basis, effective Aug. 26. The company said the split will reduce the number of its outstanding shares to about 17,...
2024-08-15 22:19
